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Immune-related Adverse Event Management for Oncology Patients
Mary Beth Casselbury RN, BSN, OCN, Lori Davis RN, BSN, OCN, Sharon Wilson RN, OCN
Lipson Cancer Institute at Rochester Regional Health System

BACKGROUND
Using Immune Checkpoint Inhibitors has led to improved
survival of patients and may be associated with multiple
immune-related adverse events(irAEs). These adverse events
can affect a wide range of organs and induce nonspecific
symptoms with delayed onset and prolonged duration. These
symptoms may or may not be reported or assessed and can
lead to life-threatening disorders. Patient education regarding
reporting side effects as well as periodic follow-up care for
patients receiving immunotherapy is essential to manage and
treat irAEs. Our team looked for evidence to support initial
and more frequent reinforcement of patient education to
determine if these interventions can manage irAEs and
thereby decrease the severity of these events.

PICO QUESTION
For oncology patients undergoing immunotherapy, how does
frequent reinforcement of patient education regarding early
recognition and management of immune-related adverse events
affect patient reporting of these events?
Population

Oncology patients undergoing immunotherapy

Intervention Reinforcement of patient education for early
recognition and communication of adverse events
Outcome

Ability of the patient to recognize and report
symptoms of adverse events

LITERATURE REVIEW

RECOMMENDED PRACTICE CHANGE

CINAHL and Medline were searched; 6 articles were reviewed
including two Level V articles and four Level VII articles.

We are planning to implement the use of the ONS Immunotherapy
Wallet Card so that patients are able to communicate effectively
with all of their providers.

SYNTHESIS
Patient education is critical to maximize early recognition and
prompt reporting of irAEs which leads to early intervention.
Oncology nurses are well positioned to provide immunotherapy
education. Encourage patients to call early and often with any
side effects. Initial and ongoing patient education helps ensure
the best quality of life and minimization for side effects and
irAEs. The key to optimizing therapies is collaborative
monitoring, evaluation, documentation and communication.
The articles we reviewed confirmed our practice. In our
research we found that the Oncology Nursing Society has a
wallet card specifically for patients on immunotherapy. This
card is used to communicate with a patient’s other providers. A
few pieces of information include: drug name, drug type and
start date of treatment.
We did not find specific guidelines for the frequency of patient
education reinforcement or for the frequency of follow ups.
Would increasing the frequency of these be beneficial? Further
studies would need to be conducted focusing on these issues.

CONCLUSION
Current practice has been Clinic RN’s providing initial education
including treatment schedule, drug teaching sheet, immunotherapy
guide pamphlet, first treatment expectations, who and when to call
and a timeline for when to expect side effects.
Telephone triage protocols assist in guiding the assessment of
symptoms and direct the patient in the appropriate management of
irAEs. Depending on the severity of the symptom a patient could be
directed to manage at home or come in that day for an office visit.
Telephone triage has noticed an increase in calls from patients being
treated with immunotherapy.
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